Your browser doesn't support javascript.
loading
Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records.
Sun, Virginia H; Heemelaar, Julius C; Hadzic, Ibrahim; Raghu, Vineet K; Wu, Chia-Yun; Zubiri, Leyre; Ghamari, Azin; LeBoeuf, Nicole R; Abu-Shawer, Osama; Kehl, Kenneth L; Grover, Shilpa; Singh, Prabhsimranjot; Suero-Abreu, Giselle A; Wu, Jessica; Falade, Ayo S; Grealish, Kelley; Thomas, Molly F; Hathaway, Nora; Medoff, Benjamin D; Gilman, Hannah K; Villani, Alexandra-Chloe; Ho, Jor Sam; Mooradian, Meghan J; Sise, Meghan E; Zlotoff, Daniel A; Blum, Steven M; Dougan, Michael; Sullivan, Ryan J; Neilan, Tomas G; Reynolds, Kerry L.
Afiliación
  • Sun VH; Harvard Medical School, Boston, MA.
  • Heemelaar JC; Cardiovascular Imaging Research Center, Massachusetts General Hospital, Boston, MA.
  • Hadzic I; Harvard Medical School, Boston, MA.
  • Raghu VK; Cardiovascular Imaging Research Center, Massachusetts General Hospital, Boston, MA.
  • Wu CY; Leiden University Medical Center, Leiden, the Netherlands.
  • Zubiri L; Harvard Medical School, Boston, MA.
  • Ghamari A; Artificial Intelligence in Medicine (AIM) Program, Mass General Brigham, Boston, MA.
  • LeBoeuf NR; Brigham and Women's Hospital, Boston, MA.
  • Abu-Shawer O; Maastricht University, Maastricht, the Netherlands.
  • Kehl KL; Harvard Medical School, Boston, MA.
  • Grover S; Cardiovascular Imaging Research Center, Massachusetts General Hospital, Boston, MA.
  • Singh P; Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA.
  • Suero-Abreu GA; Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  • Wu J; Harvard Medical School, Boston, MA.
  • Falade AS; Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA.
  • Grealish K; Harvard Medical School, Boston, MA.
  • Thomas MF; Cardiovascular Imaging Research Center, Massachusetts General Hospital, Boston, MA.
  • Hathaway N; Harvard Medical School, Boston, MA.
  • Medoff BD; Department of Dermatology, Brigham and Women's Hospital, Boston, MA.
  • Gilman HK; Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Villani AC; Department of Internal Medicine, Cleveland Clinic, Cleveland, OH.
  • Ho JS; Harvard Medical School, Boston, MA.
  • Mooradian MJ; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA.
  • Sise ME; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Zlotoff DA; Harvard Medical School, Boston, MA.
  • Blum SM; Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women's Hospital, Boston, MA.
  • Dougan M; Harvard Medical School, Boston, MA.
  • Sullivan RJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Neilan TG; Harvard Medical School, Boston, MA.
  • Reynolds KL; Cardiovascular Imaging Research Center, Massachusetts General Hospital, Boston, MA.
J Clin Oncol ; : JCO2400326, 2024 Sep 03.
Article en En | MEDLINE | ID: mdl-39226489
ABSTRACT

PURPOSE:

Current approaches to accurately identify immune-related adverse events (irAEs) in large retrospective studies are limited. Large language models (LLMs) offer a potential solution to this challenge, given their high performance in natural language comprehension tasks. Therefore, we investigated the use of an LLM to identify irAEs among hospitalized patients, comparing its performance with manual adjudication and International Classification of Disease (ICD) codes.

METHODS:

Hospital admissions of patients receiving immune checkpoint inhibitor (ICI) therapy at a single institution from February 5, 2011, to September 5, 2023, were individually reviewed and adjudicated for the presence of irAEs. ICD codes and an LLM with retrieval-augmented generation were applied to detect frequent irAEs (ICI-induced colitis, hepatitis, and pneumonitis) and the most fatal irAE (ICI-myocarditis) from electronic health records. The performance between ICD codes and LLM was compared via sensitivity and specificity with an α = .05, relative to the gold standard of manual adjudication. External validation was performed using a data set of hospital admissions from June 1, 2018, to May 31, 2019, from a second institution.

RESULTS:

Of the 7,555 admissions for patients on ICI therapy in the initial cohort, 2.0% were adjudicated to be due to ICI-colitis, 1.1% ICI-hepatitis, 0.7% ICI-pneumonitis, and 0.8% ICI-myocarditis. The LLM demonstrated higher sensitivity than ICD codes (94.7% v 68.7%), achieving significance for ICI-hepatitis (P < .001), myocarditis (P < .001), and pneumonitis (P = .003) while yielding similar specificities (93.7% v 92.4%). The LLM spent an average of 9.53 seconds/chart in comparison with an estimated 15 minutes for adjudication. In the validation cohort (N = 1,270), the mean LLM sensitivity and specificity were 98.1% and 95.7%, respectively.

CONCLUSION:

LLMs are a useful tool for the detection of irAEs, outperforming ICD codes in sensitivity and adjudication in efficiency.

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: J Clin Oncol / J. clin. oncol / Journal of clinical oncology Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: J Clin Oncol / J. clin. oncol / Journal of clinical oncology Año: 2024 Tipo del documento: Article